Iran Pharmaceuticals and Healthcare Report Q2 2008

Publication Date	April 2008
Publisher	Business Monitor
Product Type	Report
Pages	65
ISBN Number	not applicable
Product Code	BMI01690

Price

£425.00
approximately: $835 | €540

PDF immediate delivery

Order above formats by FAX

Summary

Iran's pharmaceutical market was estimated to be worth US$1,794mn in 2007, making it large in regional terms. However, per capita pharmaceutical consumption remains significantly lower than in many neighbouring Gulf states - standing at just US$25 in 2007. Access to quality healthcare, particularly in rural areas, remains a problem that will continue to hold down overall drug consumption over the forecast period. BMI expects the drug market to average 8% year-on-year (y-o-y) growth to reach a value of US$2,622mn by 2012.

Government policy is weighted towards generics and Iranian-made medicines are more likely to be reimbursed. Foreign drug- and medical device-makers tend to steer clear of a direct presence in Iran, with most limiting themselves to import businesses in partnership with local distributors. Many companies conduct their business via Gulf states such as the UAE.

Iran remains in tenth place in BMI's updated Business Environment Rankings table for the Middle East and Africa (MEA) out of 14 markets surveyed. Its business environment is considered one of the more risky in the region because of its frosty relationship with the West and biased pharmaceutical regulatory regime. However, in terms of scale, the market offers good prospects for companies willing to take on these risks.

Iran's healthcare system is strong in terms of population coverage - with at least 90% of the population having access to basic healthcare. Government efforts to increase standards in rural areas - including plans to require that doctors take postings to rural areas after completing training - should push the level of healthcare coverage closer to 100% over the forecast period.

Hospitals remain the primary access point for pharmaceuticals and, as a consequence, the prescription drug market is expected to remain dominant. Having said this, domestic manufacturers have shown an ability to develop herbal medicines, which could translate into a boost for the over-the-counter (OTC) drug market. Indeed, herbal medicines that have been developed in Iran are being well received on export markets, particularly in Central and Eastern Europe and North Africa.

Content

Executive Summary
SWOT Analysis
- Table: Iran Pharmaceuticals And Healthcare Industry SWOT
Iran Political SWOT
Iran Economic SWOT
Iran Business Environment SWOT
Business Environment Ranking Iran - Business Environment Ranking
- Table: Pharmaceutical Business Environment Ratings
Limits Of Potential Returns
Risks To Realisation Of Returns
Market Summary
Regulatory Regime
Registration Of Imports
Generic Registration
Intellectual Property (IP) Regime
Intellectual Property Disputes
Counterfeit Medicines
Pricing And Reimbursement
Industry Developments
Health Status
HIV/AIDS Situation
Iran HIV/AIDS Prevalence
Healthcare Sector
Primary Care
Secondary Care
Retail Pharmacies
Health Insurance
Regional Developments
International Collaboration
Pharmaceutical Industry
Traditional Herbal Remedies
Recent Company Activity
Research And Development
International Co-operation
Industry Forecast Sce29
Overall Market Forecast
- Table: Drug Expenditure Forecasts
Key Growth Factors - Industry
- Table: Health Expenditure Forecasts
Key Growth Factors - Macroeconomic
- Table: Iran - Economic Activity
Prescription Market Forecast
- Table: Prescription Drug Market Forecast (US$mn unless otherwise stated)
OTC Market Forecast
- Table: OTC Market Data Forecasts (US$mn unless otherwise stated)
Generics And Patented Market Forecast
- Table: Generics And Patented Market Forecasts
Medical Device Market Forecast
Iran Medical Device Market Forecast
Import/Export Market Forecast
- Table: Pharmaceutical Trade Indicators (US$mn)
Other Healthcare Data Forecasts
- Table: Other Health Indicators
Key Risks To BMI's Forecast Scenario
Competitive Landscape
Company Profiles
Multinationals
Novartis
Merck & Co
Pfizer
GlaxoSmithKline
Sanofi-Aventis
Indigenous Companies
Darou Pakhsh
Caspian Tamin Pharmaceutical Company*
Pharmieco
Pars Darou
Zahravi
Amin
Sina Darou Pharmaceutical Company
BMI Forecast Modelling
How We Generate Our Industry Forecasts
Pharmaceutical Industry
Pharmaceutical Business Environment Ratings Methodology
Ratings Overview
- Table: Pharmaceutical Business Environment Indicators
Weighting
- Table: Weighting Of Components
Sources